companies / terremotobiosciences-org
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-08 json
| total_raised | 41,000,00041.0M | ○ |
|---|---|---|
| founded | 2022 | |
| hq | SOUTH SAN FRANCISCO, CA | |
| industry | unknown | |
| stage | null |
Terremoto Biosciences is a covalent drug-discovery company creating selective small molecules that covalently bind lysine, found in nearly every protein. It targets oncology and rare disease, including undruggable targets, with a lead AKT1 inhibitor in the clinic. Its edge is lysine-based covalency beyond the cysteine residues older drugs use.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2026-04-10 | Funding round | 41,000,00041.0M | null | ○ |
| fact | status | src |
|---|---|---|
| Funding round, $41.0M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |
| date | fact | change | src |
|---|---|---|---|
| 2026-09-25latest_round: seed, $41.0M, 2026-04-10 → Funding round, $41.0M, 2026-04-10, ○ 2026-05-08 | latest_round | seed, $41.0M, 2026-04-10 → Funding round, $41.0M, 2026-04-10 | ○ 2026-05-08 |
Records begin 2026-09-24. all_changes